News & Updates

Show Multimedia Only

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

04 Jan 2022 by

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

04 Jan 2022

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

04 Jan 2022

A delayed dose reduction of tacrolimus, along with induction of basiliximab, helps suppress kidney injury in liver transplant recipients, as opposed to standard-dose tacrolimus, a recent study has found. Such benefits come with no excess risk of rejection, graft loss, or death.

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

04 Jan 2022

Lower risk of SARS-CoV-2 after booster dose

03 Jan 2022 by

Receipt of a booster dose of the BNT162b2 mRNA vaccine is tied to a reduced risk of testing positive for SARS-CoV-2, according to results of a study from Israel.

Lower risk of SARS-CoV-2 after booster dose

03 Jan 2022

COVID-19 vax in kids: Which group to target first?

30 Dec 2021 by

Children with asthma who are infected with SARS-CoV-2 virus are at an increased risk of hospitalization, especially those whose asthma is poorly controlled, compared with children without asthma, according to data from the EAVE II* study.

COVID-19 vax in kids: Which group to target first?

30 Dec 2021

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer

30 Dec 2021 by

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer

30 Dec 2021

Ovarian suppression + AI prevents recurrence in premenopausal breast cancer over long term

28 Dec 2021 by

The benefits in terms of prolonged disease-free survival (DFS) and reduced risk of recurrence with ovarian function suppression (OFS) persisted over 12–13 years in premenopausal women with hormone receptor-positive (HR+) breast cancer, according to new data from the TEXT and SOFT randomized trials presented at SABCS 2021.

Ovarian suppression + AI prevents recurrence in premenopausal breast cancer over long term

28 Dec 2021

Omicron raises new fears

28 Dec 2021 by

The threat of Omicron is real, with scientists working at breakneck speed to better understand its virulence and potential ability to evade currently approved vaccines.

Omicron raises new fears

28 Dec 2021

COMMODORE trial steers gilteritinib to the fore of AML treatment

28 Dec 2021 by

Gilteritinib provided significant survival benefit and demonstrated a favourable safety and tolerability profile in Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukaemia (R/R FLT3mut+ AML) compared with salvage chemotherapy (SC), findings from the phase III COMMODORE trial suggest.

COMMODORE trial steers gilteritinib to the fore of AML treatment

28 Dec 2021

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

28 Dec 2021 by

Venous thromboembolism (VTE) is a serious medical condition. It comprises deep vein thrombosis and pulmonary embolism. Left untreated, it could result in significant morbidity and mortality. Most patients with VTE receive anticoagulation therapy for 3 months or longer. For more than 50 years since the 1940s, vitamin K antagonists (VKAs) such as warfarin were the mainstay of oral anticoagulation therapy for VTE. As it has a narrow therapeutic index, VKAs require frequent coagulation monitoring with International Normalised Ratio (INR) to adjust and optimize the dose for each individual. As the peak effect for warfarin takes at least 4-5 days, in the initial stage of VTE, concurrent administration of daily subcutaneous injections of low molecular weight heparin (LMWH) is needed until INR reaches therapeutic levels. Due to numerous drug and dietary interactions with warfarin, regular INR monitoring is required to ensure therapeutic levels are maintained and to avoid under or overdosing.

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

28 Dec 2021

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

28 Dec 2021 by

Nonvalvular atrial fibrillation (NVAF) raises the risk of stroke by three to five times, particularly in older patients. Treating older patients with NVAF presents special challenges because of their elevated risks for both stroke and bleeding. This necessitates optimization of anticoagulant therapy by balancing efficacy and bleeding risk. Non-vitamin K antagonist oral anticoagulants (NOACs), such as apixaban, have shown advantages in safety and efficacy over warfarin, which has a very narrow therapeutic index. In an interview with Dr Soon Chao Yang, Cardiologist at The Heart Doctors Clinic, Mount Alvernia Hospital, Singapore, he shared insights on managing NVAF in older patients, as well as his experience with using apixaban in this special population.

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

28 Dec 2021

News & Updates

Filter by Specialty:

Specialty:

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

Delayed tacrolimus dose reduction plus basiliximab yields better kidney function after liver transplant

Lower risk of SARS-CoV-2 after booster dose

Lower risk of SARS-CoV-2 after booster dose

COVID-19 vax in kids: Which group to target first?

COVID-19 vax in kids: Which group to target first?

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer

Ovarian suppression + AI prevents recurrence in premenopausal breast cancer over long term

Ovarian suppression + AI prevents recurrence in premenopausal breast cancer over long term

Omicron raises new fears

Omicron raises new fears

COMMODORE trial steers gilteritinib to the fore of AML treatment

COMMODORE trial steers gilteritinib to the fore of AML treatment

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

Practical considerations in the choice of pharmacological therapy (VKAs vs NOACs) for venous thromboembolism

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing

Apixaban in the management of nonvalvular atrial fibrillation in older patients: Clinical evidence and experience sharing